Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.56 |
| ▸ | PLA2G2A | P14555 | 10/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.52 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL929869 | 0.87 | ELANE (0.56) | ALDH1A1GAAPKMMCL1PTGER4 | |
| SCHEMBL2432735 | 0.86 | PTGER4 (0.72) | ALDH1A1GAAPKMMCL1PTGER4 | |
| SCHEMBL1967040 | 0.85 | MCL1 (0.53) | ALDH1A1GAAPKMMCL1PTGER4 | |
| SCHEMBL1966056 | 0.84 | KDM4E (0.53) | ALDH1A1GAAPKMMCL1PTGER4 | |
| SCHEMBL927453 | 0.82 | PDE5A (0.56) | ALDH1A1PLA2G2APLA2G1BPTGDR2LMNA | |
| SCHEMBL14584171 | 0.82 | CYP1A2 (0.69) | ALDH1A1GAAPKMMCL1PLA2G2A | |
| SCHEMBL1216862 | 0.81 | CYP1A2 (0.51) | ALDH1A1GAAPKMMCL1PTGER4 | |
| SCHEMBL16341865 | 0.81 | PTGER4 (0.66) | ALDH1A1GAAPKMMCL1PTGER4 | |
| SCHEMBL17437919 | 0.80 | ROCK1 (0.49) | ALDH1A1GAAPKMMCL1PTGER4 | |
| SCHEMBL1964951 | 0.80 | ALDH1A1 (0.46) | ALDH1A1GAAPKMMCL1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3990433-B1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | TRANSLATUM MEDICUS INC (CA) | 2026-05-20 | — | — | EP | disclosed |
| US-12122751-B2 | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives | Translatum Medicus Inc. (CA) | 2024-10-22 | — | — | US | disclosed |
| US-20240025859-A1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | Translatum Medicus Inc. (CA) | 2024-01-25 | — | — | US | disclosed |
| US-11753382-B2 | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives | Translatum Medicus Inc. (CA) | 2023-09-12 | — | — | US | disclosed |
| US-20220363646-A1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | Translatum Medicus Inc. (CA) | 2022-11-17 | — | — | US | disclosed |
| EP-3990433-A1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | Translatum Medicus Inc. (CA) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020261158-A1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | Translatum Medicus Inc. (CA) | 2020-12-30 | — | — | WO | disclosed |
| US-20190336482-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | TRANSLATUM MEDICUS INC (CA) | 2019-11-07 | — | — | US | disclosed |
| US-20180221339-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | TRANSLATUM MEDICUS, INC. (CA) | 2018-08-09 | — | — | US | disclosed |
| EP-3310353-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | Translatum Medicus, Inc. (CA) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016203313-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | TRANSLATUM MEDICUS, INC. (CA) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12122751-B2 | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives | PCMT1, ICMT, FNTA | ALDH1A1 465/4885GAA 1017/4885PKM 1904/4885 |
| US-20180221339-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | UACA, PDE6C, EYA3 | ALDH1A1 878/4885GAA 410/4885PKM 4256/4885 |
| US-11753382-B2 | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives | PCMT1, ICMT, FNTA | ALDH1A1 465/4885GAA 1017/4885PKM 1904/4885 |
| US-20240025859-A1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | PCMT1, ICMT, FNTA | ALDH1A1 465/4885GAA 1017/4885PKM 1904/4885 |
| US-20190336482-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | UACA, PDE6C, EYA3 | ALDH1A1 878/4885GAA 410/4885PKM 4256/4885 |
| US-20220363646-A1 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | PCMT1, ICMT, FNTA | ALDH1A1 465/4885GAA 1017/4885PKM 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.